Patient-Reported Outcomes Improve with Combination Treatment for Some Patients With Hepatocellular Carcinoma
The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.